Release date: 2006-10-25
In a significant move to address ongoing concerns, the world's leading medical device company, Medtronic, has announced plans to conduct the largest randomized clinical trial to date comparing the safety of two drug-coated heart stents. The study will involve stents manufactured by both Medtronic and Johnson & Johnson, and will include around 8,000 patients across 200 clinics in Europe and other regions. The primary goal is to evaluate the risk of thrombosis following implantation of these stents. Dr. Wayne, a renowned Belgian cardiologist and one of the study’s lead researchers, emphasized that no large-scale trial has previously focused specifically on the safety profile of drug-coated stents. He believes this new study will provide more comprehensive and long-term insights into their real-world performance, helping physicians better assess their benefits and risks. Recently, at the World Heart Congress, some experts raised concerns after citing data suggesting that patients with drug-coated stents had a higher risk of blood clots compared to those with traditional bare-metal stents. This has reignited discussions about the safety of these devices within the medical community. As the research progresses, the findings are expected to play a crucial role in shaping future clinical guidelines and patient care strategies. Meditech Medical Network
Fire Alarm By Hallways,Room Smoke By Hallways,Hallways Fire Alarm,Hallways Room Smoke
Guangdong Isafenest Co.,Ltd. , https://www.isfenest.com